A phase I, single centre, open study to assess the pharmacokinetic profile and safety of a 100 mg clindamycin hydrochloride vaginal insert (CHVI) in healthy females.
Latest Information Update: 16 Oct 2014
At a glance
- Drugs Clindamycin (Primary)
- Indications Bacterial vaginosis
- Focus Pharmacokinetics
- Sponsors Controlled Therapeutics (Scotland)
- 20 Sep 2011 Actual end date (Nov 2007 ) added as reported by ClinicalTrials.gov.
- 17 Oct 2007 New trial record.